{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T03:27:59Z","timestamp":1762572479764,"version":"build-2065373602"},"reference-count":56,"publisher":"Pharmaceutical Society of Japan","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological & Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2025,11,6]]},"DOI":"10.1248\/bpb.b25-00424","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T22:06:20Z","timestamp":1762380380000},"page":"1700-1707","source":"Crossref","is-referenced-by-count":0,"title":["Inhibitory Effect of Insulin-Degrading Enzyme-Selective Inhibitor, Ii1, on the Elimination of Amyloid-<i>\u03b2<\/i>(1-40) from Rat Brain"],"prefix":"10.1248","volume":"48","author":[{"given":"Takeshi","family":"Shiiki","sequence":"first","affiliation":[{"name":"Drug Metabolism & Pharmacokinetics Research Laboratories, Daiichi Sankyo, 1\u20132\u201358 Hiromachi, Shinagawa-ku, Tokyo 140\u20138710, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumio","family":"Ohtsuki","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Microbiology, Faculty of Life Sciences, Kumamoto University, 5\u20131 Oe-honmachi, Chuo-ku, Kumamoto 862\u20130973, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Hardy J. Amyloid, the presenilins and Alzheimer\u2019s disease. Trends Neurosci.<\/i>, 20<\/b>, 154\u2013159 (1997).","DOI":"10.1016\/S0166-2236(96)01030-2"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Price DL, Tanzi RE, Borchelt DR, Sisodia SS. Alzheimer\u2019s disease: genetic studies and transgenic models. Annu. Rev. Genet.<\/i>, 32<\/b>, 461\u2013493 (1998).","DOI":"10.1146\/annurev.genet.32.1.461"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Selkoe DJ. The cell biology of \u03b2-amyloid precursor protein and presenilin in Alzheimer\u2019s disease. Trends Cell Biol.<\/i>, 8<\/b>, 447\u2013453 (1998).","DOI":"10.1016\/S0962-8924(98)01363-4"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Bateman RJ, Munsell LY, Morris JC, Swarm R, Yarasheski KE, Holtzman DM. Human amyloid-\u03b2 synthesis and clearance rates as measured in cerebrospinal fluid in vivo<\/i>. Nat. Med.<\/i>, 12<\/b>, 856\u2013861 (2006).","DOI":"10.1038\/nm1438"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Selkoe DJ. Clearing the brain\u2019s amyloid cobwebs. Neuron<\/i>, 32<\/b>, 177\u2013180 (2001).","DOI":"10.1016\/S0896-6273(01)00475-5"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P. Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol.<\/i>, 5<\/b>, 64\u201374 (2006).","DOI":"10.1016\/S1474-4422(05)70284-2"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Gudala K, Bansal D, Schifano F, Bhansali A. Diabetes mellitus and risk of dementia: a meta-analysis of prospective observational studies. J. Diabetes Investig.<\/i>, 4<\/b>, 640\u2013650 (2013).","DOI":"10.1111\/jdi.12087"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Samuel VT, Shulman GI. Mechanisms for insulin resistance: common threads and missing links. Cell<\/i>, 148<\/b>, 852\u2013871 (2012).","DOI":"10.1016\/j.cell.2012.02.017"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Steen E, Terry BM, Rivera EJ, Cannon JL, Neely TR, Tavares R, Xu XJ, Wands JR, de la Monte SM. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer\u2019s disease\u2014is this type 3 diabetes? J. Alzheimers Dis.<\/i>, 7<\/b>, 63\u201380 (2005).","DOI":"10.3233\/JAD-2005-7107"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Bomfim TR, Forny-Germano L, Sathler LB, Brito-Moreira J, Houzel JC, Decker H, Silverman MA, Kazi H, Melo HM, McClean PL, Holscher C, Arnold SE, Talbot K, Klein WL, Munoz DP, Ferreira ST, De Felice FG. An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer\u2019s disease-associated A\u03b2 oligomers. J. Clin. Invest.<\/i>, 122<\/b>, 1339\u20131353 (2012).","DOI":"10.1172\/JCI57256"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Talbot K, Wang HY, Kazi H, Han LY, Bakshi KP, Stucky A, Fuino RL, Kawaguchi KR, Samoyedny AJ, Wilson RS, Arvanitakis Z, Schneider JA, Wolf BA, Bennett DA, Trojanowski JQ, Arnold SE. Demonstrated brain insulin resistance in Alzheimer\u2019s disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J. Clin. Invest.<\/i>, 122<\/b>, 1316\u20131338 (2012).","DOI":"10.1172\/JCI59903"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) McNay EC, Recknagel AK. Brain insulin signaling: a key component of cognitive processes and a potential basis for cognitive impairment in type 2 diabetes. Neurobiol. Learn. Mem.<\/i>, 96<\/b>, 432\u2013442 (2011).","DOI":"10.1016\/j.nlm.2011.08.005"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Shiiki T, Ohtsuki S, Kurihara A, Naganuma H, Nishimura K, Tachikawa M, Hosoya K, Terasaki T. Brain insulin impairs amyloid-\u03b2(1-40) clearance from the brain. J. Neurosci.<\/i>, 24<\/b>, 9632\u20139637 (2004).","DOI":"10.1523\/JNEUROSCI.2236-04.2004"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Hoy SM. Lecanemab: first approval. Drugs<\/i>, 83<\/b>, 359\u2013365 (2023).","DOI":"10.1007\/s40265-023-01851-2"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Ito S, Matsumiya K, Ohtsuki S, Kamiie J, Terasaki T. Contributions of degradation and brain-to-blood elimination across the blood-brain barrier to cerebral clearance of human amyloid-\u03b2 peptide(1-40) in mouse brain. J. Cereb. Blood Flow Metab.<\/i>, 33<\/b>, 1770\u20131777 (2013).","DOI":"10.1038\/jcbfm.2013.125"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Adamek RN, Suire CN, Stokes RW, Brizuela MK, Cohen SM, Leissring MA. Hydroxypyridinethione inhibitors of human insulin-degrading enzyme. ChemMedChem<\/i>, 16<\/b>, 1776\u20131787 (2021).","DOI":"10.1002\/cmdc.202100111"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Leissring MA, Malito E, Hedouin S, Reinstatler L, Sahara T, Abdul-Hay SO, Choudhry S, Maharvi GM, Fauq AH, Huzarska M, May PS, Choi S, Logan TP, Turk BE, Cantley LC, Manolopoulou M, Tang WJ, Stein RL, Cuny GD, Selkoe DJ. Designed inhibitors of insulin-degrading enzyme regulate the catabolism and activity of insulin. PLoS One<\/i>, 5<\/b>, e10504 (2010).","DOI":"10.1371\/journal.pone.0010504"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Kakee A, Terasaki T, Sugiyama Y. Brain efflux index as a novel method of analyzing efflux transport at the blood-brain barrier. J. Pharmacol. Exp. Ther.<\/i>, 277<\/b>, 1550\u20131559 (1996).","DOI":"10.1016\/S0022-3565(25)13107-8"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Ito S, Ohtsuki S, Kamiie J, Nezu Y, Terasaki T. Cerebral clearance of human amyloid-\u03b2 peptide (1-40) across the blood-brain barrier is reduced by self-aggregation and formation of low-density lipoprotein receptor-related protein-1 ligand complexes. J. Neurochem.<\/i>, 103<\/b>, 2482\u20132490 (2007).","DOI":"10.1111\/j.1471-4159.2007.04938.x"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Morrison JF. Kinetics of the reversible inhibition of enzyme-catalysed reactions by tight-binding inhibitors. Biochim. Biophys. Acta<\/i>, 185<\/b>, 269\u2013286 (1969).","DOI":"10.1016\/0005-2744(69)90420-3"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Cheng Y, Prusoff WH. Relationship between the inhibition constant (KI<\/sub>) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol.<\/i>, 22<\/b>, 3099\u20133108 (1973).","DOI":"10.1016\/0006-2952(73)90196-2"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Iwata N, Tsubuki S, Takaki Y, Watanabe K, Sekiguchi M, Hosoki E, Kawashima-Morishima M, Lee HJ, Hama E, Sekine-Aizawa Y, Saido TC. Identification of the major A\u03b21-42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition. Nat. Med.<\/i>, 6<\/b>, 143\u2013150 (2000).","DOI":"10.1038\/72237"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Iwata N, Tsubuki S, Takaki Y, Shirotani K, Lu B, Gerard NP, Gerard C, Hama E, Lee HJ, Saido TC. Metabolic regulation of brain A\u03b2 by neprilysin. Science<\/i>, 292<\/b>, 1550\u20131552 (2001).","DOI":"10.1126\/science.1059946"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Tanzi RE, Moir RD, Wagner SL. Clearance of Alzheimer\u2019s A\u03b2 peptide: the many roads to perdition. Neuron<\/i>, 43<\/b>, 605\u2013608 (2004).","DOI":"10.1016\/S0896-6273(04)00533-1"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Morelli L, Llovera RE, Mathov I, Lue LF, Frangione B, Ghiso J, Castano EM. Insulin-degrading enzyme in brain microvessels: proteolysis of amyloid \u03b2 vasculotropic variants and reduced activity in cerebral amyloid angiopathy. J. Biol. Chem.<\/i>, 279<\/b>, 56004\u201356013 (2004).","DOI":"10.1074\/jbc.M407283200"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) P\u00e9rez A, Morelli L, Cresto JC, Castano EM. Degradation of soluble amyloid \u03b2-peptides 1-40, 1-42, and the Dutch variant 1-40Q by insulin degrading enzyme from Alzheimer disease and control brains. Neurochem. Res.<\/i>, 25<\/b>, 247\u2013255 (2000).","DOI":"10.1023\/A:1007527721160"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Wang DS, Dickson DW, Malter JS. \u03b2-Amyloid degradation and Alzheimer\u2019s disease. J. Biomed. Biotechnol.<\/i>, 2006<\/b>, 58406 (2006).","DOI":"10.1155\/JBB\/2006\/58406"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Zhao L, Teter B, Morihara T, Lim GP, Ambegaokar SS, Ubeda OJ, Frautschy SA, Cole GM. Insulin-degrading enzyme as a downstream target of insulin receptor signaling cascade: implications for Alzheimer\u2019s disease intervention. J. Neurosci.<\/i>, 24<\/b>, 11120\u201311126 (2004).","DOI":"10.1523\/JNEUROSCI.2860-04.2004"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Ho L, Qin W, Pompl PN, Xiang Z, Wang J, Zhao Z, Peng Y, Cambareri G, Rocher A, Mobbs CV, Hof PR, Pasinetti GM. Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer\u2019s disease. FASEB J.<\/i>, 18<\/b>, 902\u2013904 (2004).","DOI":"10.1096\/fj.03-0978fje"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Nagano H, Ito S, Masuda T, Ohtsuki S. Effect of insulin receptor-knockdown on the expression levels of blood-brain barrier functional proteins in human brain microvascular endothelial cells. Pharm. Res.<\/i>, 39<\/b>, 1561\u20131574 (2022).","DOI":"10.1007\/s11095-021-03131-8"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Tang WJ. Targeting insulin-degrading enzyme to treat type 2 diabetes mellitus. Trends Endocrinol. Metab.<\/i>, 27<\/b>, 24\u201334 (2016).","DOI":"10.1016\/j.tem.2015.11.003"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Leissring MA, Lu A, Condron MM, Teplow DB, Stein RL, Farris W, Selkoe DJ. Kinetics of amyloid \u03b2-protein degradation determined by novel fluorescence- and fluorescence polarization-based assays. J. Biol. Chem.<\/i>, 278<\/b>, 37314\u201337320 (2003).","DOI":"10.1074\/jbc.M305627200"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Ito S, Ohtsuki S, Terasaki T. Functional characterization of the brain-to-blood efflux clearance of human amyloid-\u03b2 peptide (1-40) across the rat blood-brain barrier. Neurosci. Res.<\/i>, 56<\/b>, 246\u2013252 (2006).","DOI":"10.1016\/j.neures.2006.07.006"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Ito S, Ohtsuki S, Murata S, Katsukura Y, Suzuki H, Funaki M, Tachikawa M, Terasaki T. Involvement of insulin-degrading enzyme in insulin- and atrial natriuretic peptide-sensitive internalization of amyloid-\u03b2 peptide in mouse brain capillary endothelial cells. J. Alzheimers Dis.<\/i>, 38<\/b>, 185\u2013200 (2014).","DOI":"10.3233\/JAD-122077"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Shen Y, Joachimiak A, Rosner MR, Tang WJ. Structures of human insulin-degrading enzyme reveal a new substrate recognition mechanism. Nature<\/i>, 443<\/b>, 870\u2013874 (2006).","DOI":"10.1038\/nature05143"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Miners JS, Barua N, Kehoe PG, Gill S, Love S. A\u03b2-degrading enzymes: potential for treatment of Alzheimer disease. J. Neuropathol. Exp. Neurol.<\/i>, 70<\/b>, 944\u2013959 (2011).","DOI":"10.1097\/NEN.0b013e3182345e46"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Akiyama H, Shii K, Yokono K, Yonezawa K, Sato S, Watanabe K, Baba S. Cellular localization of insulin-degrading enzyme in rat liver using monoclonal antibodies specific for this enzyme. Biochem. Biophys. Res. Commun.<\/i>, 155<\/b>, 914\u2013922 (1988).","DOI":"10.1016\/S0006-291X(88)80583-7"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Duckworth WC, Bennett RG, Hamel FG. A direct inhibitory effect of insulin on a cytosolic proteolytic complex containing insulin-degrading enzyme and multicatalytic proteinase. J. Biol. Chem.<\/i>, 269<\/b>, 24575\u201324580 (1994).","DOI":"10.1016\/S0021-9258(17)31430-8"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Bennett RG, Duckworth WC, Hamel FG. Degradation of amylin by insulin-degrading enzyme. J. Biol. Chem.<\/i>, 275<\/b>, 36621\u201336625 (2000).","DOI":"10.1074\/jbc.M006170200"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) Authier F, Cameron PH, Taupin V. Association of insulin-degrading enzyme with a 70 kDa cytosolic protein in hepatoma cells. Biochem. J.<\/i>, 319<\/b>, 149\u2013158 (1996).","DOI":"10.1042\/bj3190149"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41) Morita M, Kurochkin IV, Motojima K, Goto S, Takano T, Okamura S, Sato R, Yokota S, Imanaka T. Insulin-degrading enzyme exists inside of rat liver peroxisomes and degrades oxidized proteins. Cell Struct. Funct.<\/i>, 25<\/b>, 309\u2013315 (2000).","DOI":"10.1247\/csf.25.309"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42) Goldfine ID, Williams JA, Bailey AC, Wong KY, Iwamoto Y, Yokono K, Baba S, Roth RA. Degradation of insulin by isolated mouse pancreatic acini: evidence for cell surface protease activity. Diabetes<\/i>, 33<\/b>, 64\u201372 (1984).","DOI":"10.2337\/diabetes.33.1.64"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43) Seta K, Hayashi T, Sugawara A, Kasuno K, Watanabe S, Sumi Y, Kijima Y, Kawaguchi K, Kotake C, Seo T, Toda T, Kuwahara T. Atrial natriuretic peptide as a preload depressor in acute renal failure secondary to congestive heart failure. Ren. Fail.<\/i>, 20<\/b>, 717\u2013723 (1998).","DOI":"10.3109\/08860229809045168"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44) Dorfman VB, Pasquini L, Riudavets M, Lopez-Costa JJ, Villegas A, Troncoso JC, Lopera F, Castano EM, Morelli L. Differential cerebral deposition of IDE and NEP in sporadic and familial Alzheimer\u2019s disease. Neurobiol. Aging<\/i>, 31<\/b>, 1743\u20131757 (2010).","DOI":"10.1016\/j.neurobiolaging.2008.09.016"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45) Kurklinsky S, Abdul-Hay SO, McGuire MP, Howard EA, Knight J, Leissring MA. The blood glucose-lowering effect of racecadotril is not attributable to inhibition of insulin-degrading enzyme. Horm. Metab. Res.<\/i>, 46<\/b>, 73\u201374 (2014).","DOI":"10.1055\/s-0033-1353211"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46) Deane R, Du Yan S, Submamaryan RK, et al<\/i>. RAGE mediates amyloid-\u03b2 peptide transport across the blood-brain barrier and accumulation in brain. Nat. Med.<\/i>, 9<\/b>, 907\u2013913 (2003).","DOI":"10.1038\/nm890"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47) Deane R, Singh I, Sagare AP, Bell RD, Ross NT, LaRue B, Love R, Perry S, Paquette N, Deane RJ, Thiyagarajan M, Zarcone T, Fritz G, Friedman AE, Miller BL, Zlokovic BV. A multimodal RAGE-specific inhibitor reduces amyloid \u03b2-mediated brain disorder in a mouse model of Alzheimer disease. J. Clin. Invest.<\/i>, 122<\/b>, 1377\u20131392 (2012).","DOI":"10.1172\/JCI58642"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48) Burstein AH, Sabbagh M, Andrews R, Valcarce C, Dunn I, Altstiel L. Development of azeliragon, an oral small molecule antagonist of the receptor for advanced glycation endproducts, for the potential slowing of loss of cognition in mild Alzheimer\u2019s disease. J. Prev. Alzheimers Dis.<\/i>, 5<\/b>, 149\u2013154 (2018).","DOI":"10.14283\/jpad.2018.18"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49) Hudson BI, Carter AM, Harja E, Kalea AZ, Arriero M, Yang H, Grant PJ, Schmidt AM. Identification, classification, and expression of RAGE gene splice variants. FASEB J.<\/i>, 22<\/b>, 1572\u20131580 (2008).","DOI":"10.1096\/fj.07-9909com"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50) Sturchler E, Galichet A, Weibel M, Leclerc E, Heizmann CW. Site-specific blockade of RAGE-Vd<\/sub> prevents amyloid-beta oligomer neurotoxicity. J. Neurosci.<\/i>, 28<\/b>, 5149\u20135158 (2008).","DOI":"10.1523\/JNEUROSCI.4878-07.2008"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51) Yan SF, Ramasamy R, Schmidt AM. The RAGE axis: a fundamental mechanism signaling danger to the vulnerable vasculature. Circ. Res.<\/i>, 106<\/b>, 842\u2013853 (2010).","DOI":"10.1161\/CIRCRESAHA.109.212217"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52) Deane RJ. Is RAGE still a therapeutic target for Alzheimer\u2019s disease? Future Med. Chem.<\/i>, 4<\/b>, 915\u2013925 (2012).","DOI":"10.4155\/fmc.12.51"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53) Hubert P, Roncarati P, Demoulin S, Pilard C, Ancion M, Reynders C, Lerho T, Bruyere D, Lebeau A, Radermecker C, Meunier M, Nokin MJ, Hendrick E, Peulen O, Delvenne P, Herfs M. Extracellular HMGB1 blockade inhibits tumor growth through profoundly remodeling immune microenvironment and enhances checkpoint inhibitor-based immunotherapy. J. Immunother. Cancer<\/i>, 9<\/b>, e001966 (2021).","DOI":"10.1136\/jitc-2020-001966"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54) Shibata M, Yamada S, Kumar SR, Calero M, Bading J, Frangione B, Holtzman DM, Miller CA, Strickland DK, Ghiso J, Zlokovic BV. Clearance of Alzheimer\u2019s amyloid-\u03b2(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J. Clin. Invest.<\/i>, 106<\/b>, 1489\u20131499 (2000).","DOI":"10.1172\/JCI10498"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55) Cirrito JR, Deane R, Fagan AM, Spinner ML, Parsadanian M, Finn MB, Jiang H, Prior JL, Sagare A, Bales KR, Paul SM, Zlokovic BV, Piwnica-Worms D, Holtzman DM. P-glycoprotein deficiency at the blood-brain barrier increases amyloid-\u03b2 deposition in an Alzheimer disease mouse model. J. Clin. Invest.<\/i>, 115<\/b>, 3285\u20133290 (2005).","DOI":"10.1172\/JCI25247"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56) Ito S, Ueno T, Ohtsuki S, Terasaki T. Lack of brain-to-blood efflux transport activity of low-density lipoprotein receptor-related protein-1 (LRP-1) for amyloid-\u03b2 peptide(1-40) in mouse: involvement of an LRP-1-independent pathway. J. Neurochem.<\/i>, 113<\/b>, 1356\u20131363 (2010).","DOI":"10.1111\/j.1471-4159.2010.06708.x"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/48\/11\/48_b25-00424\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T03:23:34Z","timestamp":1762572214000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/48\/11\/48_b25-00424\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,6]]},"references-count":56,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b25-00424","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"type":"print","value":"0918-6158"},{"type":"electronic","value":"1347-5215"}],"subject":[],"published":{"date-parts":[[2025,11,6]]},"article-number":"b25-00424"}}